Literature DB >> 19901068

Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans.

Krishanthi S Subramaniam1, Kausik Datta, Matthew S Marks, Liise-Anne Pirofski.   

Abstract

Cryptococcus neoformans causes severe, and often fatal, disease (cryptococcosis) in immunocompromised patients, particularly in those with HIV/AIDS. Although resistance to cryptococcosis requires intact T-cell immunity, a possible role for antibody/B cells in protection against natural disease has not been definitively established. Previous studies of the antibody response to the C. neoformans capsular polysaccharide glucuronoxylomannan (GXM) have demonstrated that patients who are at increased risk for cryptococcosis have lower serum levels of GXM-reactive IgM than those who are not at risk, leading to the hypothesis that IgM might contribute to resistance to cryptococcosis. To determine the influence of IgM on susceptibility to systemic cryptococcosis in a murine model, we compared the survival of mice deficient in serum IgM (secretory IgM deficient [sIgM(-/-)]) and C57BL/6 x 129Sv (control) mice after intraperitoneal infection with C. neoformans strain 24067 and analyzed the splenic B- and T-cell subsets by flow cytometry and the serum and splenic cytokine/chemokine and serum antibody profiles of each mouse strain. The results showed that sIgM(-/-) mice survived significantly longer than control mice when challenged with 10(5) CFU of C. neoformans 24067. Naïve sIgM(-/-) mice had higher levels of B-1 (CD5(+)) B cells, proinflammatory mediators (interleukin-6 [IL-6], IL-1beta, MIP-1beta, tumor necrosis factor alpha [TNF-alpha], and gamma interferon [IFN-gamma]), and anti-inflammatory mediators (IL-10 and IL-13) and significantly higher titers of GXM-specific IgG2a 3 weeks postinfection. In addition, CD5(+) splenocytes from both mouse strains had fungicidal activity against C. neoformans. Taken together, these results suggest that the inflammatory milieu in sIgM(-/-) mice might confer enhanced resistance to systemic cryptococcosis, stemming in part from the antifungal activity of B-1 B cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901068      PMCID: PMC2798234          DOI: 10.1128/IAI.00506-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  79 in total

1.  Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide.

Authors:  J E Sanford; D M Lupan; A M Schlageter; T R Kozel
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

2.  Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice.

Authors:  K Kawakami; Y Koguchi; M H Qureshi; Y Kinjo; S Yara; A Miyazato; M Kurimoto; K Takeda; S Akira; A Saito
Journal:  FEMS Microbiol Lett       Date:  2000-05-01       Impact factor: 2.742

3.  Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.

Authors:  S A Mohamedi; J M Brewer; J Alexander; A W Heath; R Jennings
Journal:  Vaccine       Date:  2000-04-14       Impact factor: 3.641

4.  Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis.

Authors:  D P da Fonseca; J Frerichs; M Singh; H Snippe; A F Verheul
Journal:  Vaccine       Date:  2000-08-15       Impact factor: 3.641

5.  Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide.

Authors:  A M Schlageter; T R Kozel
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

6.  Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10.

Authors:  A O'Garra; R Chang; N Go; R Hastings; G Haughton; M Howard
Journal:  Eur J Immunol       Date:  1992-03       Impact factor: 5.532

7.  Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.

Authors:  Robert W Maitta; Kausik Datta; Qing Chang; Robin X Luo; Bradley Witover; Krishanthi Subramaniam; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Protective murine monoclonal antibodies to Cryptococcus neoformans.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

9.  B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection.

Authors:  N Baumgarth; O C Herman; G C Jager; L E Brown; L A Herzenberg; J Chen
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

10.  Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.

Authors:  J Mukherjee; A Casadevall; M D Scharff
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  10 in total

Review 1.  The importance of natural IgM: scavenger, protector and regulator.

Authors:  Michael R Ehrenstein; Clare A Notley
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

2.  IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms.

Authors:  Wendy A Szymczak; Rani S Sellers; Liise-anne Pirofski
Journal:  Am J Pathol       Date:  2012-02-16       Impact factor: 4.307

Review 3.  Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  Cell Host Microbe       Date:  2012-05-17       Impact factor: 21.023

Review 4.  Host immunity to Cryptococcus neoformans.

Authors:  Soma Rohatgi; Liise-Anne Pirofski
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

5.  The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans.

Authors:  Krishanthi S Subramaniam; Kausik Datta; Eric Quintero; Catherine Manix; Matthew S Marks; Liise-Anne Pirofski
Journal:  J Immunol       Date:  2010-04-19       Impact factor: 5.422

6.  Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection.

Authors:  Soma Rohatgi; Liise-anne Pirofski
Journal:  J Immunol       Date:  2012-11-21       Impact factor: 5.422

Review 7.  Differential impact of Toll-like receptor signaling on distinct B cell subpopulations.

Authors:  Almut Meyer-Bahlburg; David J Rawlings
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

8.  Innate Immune Responses to Cryptococcus.

Authors:  Lena J Heung
Journal:  J Fungi (Basel)       Date:  2017-07-02

9.  Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis.

Authors:  Priya Uppuluri; Shakti Singh; Abdullah Alqarihi; Clint S Schmidt; John P Hennessey; Michael R Yeaman; Scott G Filler; John E Edwards; Ashraf S Ibrahim
Journal:  Front Immunol       Date:  2018-06-15       Impact factor: 7.561

Review 10.  Immunoglobulin M in Health and Diseases: How Far Have We Come and What Next?

Authors:  Katelyn Jones; Anca F Savulescu; Frank Brombacher; Sabelo Hadebe
Journal:  Front Immunol       Date:  2020-10-30       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.